leadf
logo-loader
viewValeo Pharma Inc.

Valeo Pharma appoints new president and COO; Saviuk continues as CEO and becomes vice-chairman

Fasano has over 25 years' experience in managing strategic affiliates in Canada, Europe, and Latin America

Valeo Pharma Inc. -
Quebec-headquartered Valeo commercializes innovative prescription products in Canada, with a focus on neurodegenerative diseases, oncology and hospital specialty products

Valeo Pharma Inc (CSE:VPH) (OTCQB:VPHI) (FRA:VP2) has named seasoned executive Frederic Fasano as its president and chief operating officer (COO), a newly-created role, as the company continues its growth story. 

Fasano has over 25 years' experience in managing strategic affiliates in Canada, Europe, and Latin America, and before joining Valeo, he was president and CEO of Servier Canada, a fully integrated affiliate of Servier Group - the independent, international and independent pharma group.

READ: Valeo Pharma notes research says Hesperco antioxidant capsules contain compound with potential coronavirus treatment application

"This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years," said Steve Saviuk, who, himself, continues as Valeo's CEO but also becomes vice-chairman.

Richard MacKay remains the chairman of the board.

"I am very excited to join Steve and his team at such a pivotal time in the corporate development of Valeo," Fasano told investors on Monday.

"Valeo is very well positioned to become an anchor Canadian pharma company aiming at bringing innovative treatments to patients.

"Life sciences have been incredibly productive and disruptive in recent times and we at Valeo want to reinvent the way this amazing science is reaching patients."

Quebec-headquartered Valeo commercializes innovative prescription products in Canada with a focus on neurodegenerative diseases, oncology and hospital specialty products.

Contact the author at giles@proactiveinvestors.com

Quick facts: Valeo Pharma Inc.

Price: 0.99 CAD

CSE:VPH
Market: CSE
Market Cap: $58.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Valeo Pharma Inc. named herein, including the promotion by the Company of Valeo Pharma Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Montreal Heart Institute starting a clinical trial with Hesperco for...

Valeo Pharma (CSE: VPH-OTCQB: VPHIF) CEO Steve Saviuk and Ingenew Pharma CEO Pierre Laurin joined Steve Darling from Proactive to provide an update on what will be the role and involvement of Valeo in the Hesperco clinical program and clinical trial conducted by the Montreal Heart...

1 week, 2 days ago

2 min read